In another major development, Suven Life's SUVN-502 (Masupirdine) phase 2a study for Alzheimer's disease failed to meet its pre-specified primary endpoint in proof of concept (POC) study. This is a major setback on this flagship drug. Nonetheless, the future financial impact may be minimal mainly because the company has already expensed R&D; cost in P&L.; On the regulatory front, the USFDA has classified Ipca Labs' formulations facility at Piparia, Silvassa as official action indicated (OAI). The facility had received three observations after the cGMP inspection conducted from...